COVID-19 and the effect on cardiovascular diseases, CV clinical trials and CV outcome trials

April 28, 2020

For clinical researchers involved with COVID-19, understanding its impact on cardiovascular homeostasis and the underlying pathophysiology is essential. In this article, Dr. Lazar Mandinov, Sr. Medical Director at Parexel, outlines the most significant current evidence and uncertainties, and provides practical guidance for conducting clinical trials related to COVID-19.

Previous Flipbook
Remote Desktop cGMP Audits Factsheet
Remote Desktop cGMP Audits Factsheet

Next Flipbook
5 strategies for mitigating the impact of COVID-19 on clinical trials
5 strategies for mitigating the impact of COVID-19 on clinical trials